TELA BIO ($TELA) is expected to release its quarterly earnings data on Thursday, November 13th after market close, per Finnhub. Analysts are expecting revenue of $22,223,760 and earnings of -$0.20 per share.
You can see Quiver Quantitative's $TELA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TELA BIO Hedge Fund Activity
We have seen 16 institutional investors add shares of TELA BIO stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 1,416,323 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,747,666
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,233,623 shares (+31.8%) to their portfolio in Q2 2025, for an estimated $2,393,228
- MINK BROOK ASSET MANAGEMENT LLC removed 357,092 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $692,758
- PENTWATER CAPITAL MANAGEMENT LP removed 183,755 shares (-18.4%) from their portfolio in Q2 2025, for an estimated $356,484
- RENAISSANCE TECHNOLOGIES LLC removed 177,111 shares (-72.5%) from their portfolio in Q2 2025, for an estimated $343,595
- VANGUARD GROUP INC removed 111,694 shares (-5.8%) from their portfolio in Q3 2025, for an estimated $166,424
- HBK SORCE ADVISORY LLC added 100,365 shares (+inf%) to their portfolio in Q3 2025, for an estimated $149,543
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TELA BIO Government Contracts
We have seen $21,000 of award payments to $TELA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- SURGICAL IMPLANTS: $10,500
- OVITEX 1S PERMANENT 25X30: $10,500
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
